Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-13
2008-05-13
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S146000, C548S200000, C548S215000, C548S247000, C546S184000, C546S268100, C546S281700, C546S284700, C544S224000, C544S336000, C544S358000, C549S013000, C549S020000, C549S429000, C549S484000, C514S365000, C514S374000
Reexamination Certificate
active
10486396
ABSTRACT:
The present invention provides a novel compound having an excellent PPAR agonist action. More specifically, it provides a compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them.Wherein a, b and c are the same as or different from one another and each represents 0 to 4; R1to R6are the same as or different from one another and each represents a hydrogen atom, a hydroxyl group, a cyano group, a halogen atom, etc.;A1and A2are the same as or different from each other and each represents a single bond, an oxygen atom, etc.;L, M and T each represent a single bond, an alkylene group having one to six carbon atoms, etc.;W represents a carboxyl group;the partial structure represented by the formula:represents a single bond or a double bond;X represents a single bond, an oxygen atom, —NRx1CQ1O—, etc.;Y represents Y1—Y2— (wherein Y1represents a 5 to 14-membered aromatic ring having one to four substituents, etc.; and Y2represents a single bond or a 5 to 14-membered aromatic ring); andthe ring Z represents a 5 to 14-membered aromatic ring which have one to four substituents selected form the above-mentioned Group A, may have one or more hetero atoms and may be partially saturated.
REFERENCES:
patent: 6506797 (2003-01-01), Nomura et al.
patent: 6884821 (2005-04-01), Shinoda et al.
patent: 7244861 (2007-07-01), Matsuura et al.
patent: 7253178 (2007-08-01), Harada et al.
patent: 2004/0102634 (2004-05-01), Matsuura et al.
patent: 2004/0116708 (2004-06-01), Harada et al.
patent: 2004/0138271 (2004-07-01), Matsuura et al.
patent: 2004/0214888 (2004-10-01), Matsuura et al.
patent: 2005/0014833 (2005-01-01), Clark et al.
patent: 3026924 (1982-02-01), None
patent: 0028063 (1981-05-01), None
patent: 0219308 (1987-04-01), None
patent: 0 543 662 (1993-05-01), None
patent: 1026149 (2000-08-01), None
patent: 57-064639 (1982-04-01), None
patent: 9-48771 (1997-02-01), None
patent: 11-152269 (1999-06-01), None
patent: 2001-55367 (2001-02-01), None
patent: 2001-261612 (2001-09-01), None
patent: WO-89/03819 (1989-05-01), None
patent: WO-90/06920 (1990-06-01), None
patent: WO-94/01420 (1994-01-01), None
patent: WO-94/13650 (1994-06-01), None
patent: WO-95/03288 (1995-02-01), None
patent: WO 99/04815 (1999-02-01), None
patent: WO 99/16758 (1999-04-01), None
patent: WO 99/18066 (1999-04-01), None
patent: WO 99/20275 (1999-04-01), None
patent: WO-99/65897 (1999-12-01), None
patent: WO 00/04011 (2000-01-01), None
patent: WO-00/64876 (2000-11-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 00/75103 (2000-12-01), None
patent: WO-01/55086 (2001-02-01), None
patent: WO-01/21578 (2001-03-01), None
patent: WO-01/25181 (2001-04-01), None
patent: WO-01/38325 (2001-05-01), None
patent: WO-01/55085 (2001-08-01), None
patent: WO-01/92201 (2001-12-01), None
patent: WO-02/100812 (2002-01-01), None
patent: WO-02/079162 (2002-10-01), None
patent: WO-02/080899 (2002-10-01), None
patent: WO-02/081428 (2002-10-01), None
patent: WO 02/083616 (2002-10-01), None
patent: WO 02/098840 (2002-12-01), None
patent: WO-03/016265 (2003-02-01), None
Jurgen M. Lehmann et al.; The Journal of Biological Chemistry; vol. 270, No. 22, Issue of June 2, pp. 12953-12956, 1995.
Timothy M. Willson et al.; Journal of Medicinal Chemistry; vol. 43, No. 4, Feb. 24, 2000, pp. 527-550.
Philip M. Barger et al.; Trends Cardiovasc. Med., vol. 10, No. 6, 2000, pp. 238-245.
Bernard Hulin et al.; Current Pharmaceutical Design, 2, No. 1, pp. 85-102, 1996.
D.R. Buckle et al.; Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 17, pp. 2121-2126, 1996.
Clarie Bastie et al.; The Journal of Biological Chemistry, vol. 274, No. 31, Issue of July 30, pp. 21920-21925, 1999.
Miyachi et al., Bioorganic & Medicinal Chemistry Letters, vol. 12, 2002, pp. 77-80.
“Nuovi Coloranti Per Miste Poliestere/Cotone” Tinctoria, 1996, vol. 93, No. 5, pp. 34-39.
Gibson et al., European Journal of Medicinal Chemistry, vol. 32, No. 10, 1997, pp. 823-831.
Young et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 284, No. 2, 1997, pp. 751-759.
Haigh et al., Bioorganic & Medicinal Chemistry, vol. 7, No. 5, 1999, pp. 821-830.
Lavoie et al., Bioorganic & Medicinal Chemistry Letters, vol. 11, No. 21, pp. 2847-2850.
Li et al., Hcaplus 2006:256663, “Peroxisome proliferators-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis”, Annual Review of Pharmacology and Toxicology, 2006.
Kurtz, Hcaplus 2006:551484, “New treatment strategies for patients with hypertension and insulin resistance”, American Journal of Medicine, 2006.
Clark Richard
Emori Eita
Hihara Taro
Inoue Takashi
Kasai Shunji
Birch & Stewart Kolasch & Birch, LLP
Eisai Co. Ltd.
Shameem Golam M. M.
LandOfFree
Cyclic compound and PPAR agonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic compound and PPAR agonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic compound and PPAR agonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3908883